All News
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores.
Synovial hypertrophy most responsive.
Hands and feet, wrist and knees most affected and responsive.
@RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Robert B Chao, MD doctorRBC ( View Tweet)
#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Novel composite DAPSA LDA +IGA < or = to 1 may be a reliable predictor in long-term PsA skin/joint response (and easier to get than PASDAS in clinic.) @AlexisOgdie #EULAR2022 POS0082 @RheumNow https://t.co/dmMjGcsIcm https://t.co/BHRlGenCyl
Dr. Rachel Tate uptoTate ( View Tweet)
Style guide: welcome to the modern era of #EULAR2022
(and here I am, stuck-in-the-mud still wearing my collared shirt/blue blazer)
@RheumNow https://t.co/MXXHWF7Q47
David Liew drdavidliew ( View Tweet)
More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK
Links:
Richard Conway RichardPAConway ( View Tweet)
Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c
Links:
Richard Conway RichardPAConway ( View Tweet)
Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b
Links:
Richard Conway RichardPAConway ( View Tweet)
Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B
Links:
Richard Conway RichardPAConway ( View Tweet)
@KDAO2011 @RheumNow Exactly: they asked general questions about what is important to patients - likelihood of success, tolerance, infectious risks as below.
@RheumNow https://t.co/DZieop9M45
Eric Dein ericdeinmd ( View Tweet)
van der Pol et al from BeST study. No association with diabetes for pred use HR 0.588 (95%CI 0.285; 1.21) nor cumulative pred dose OR 1.04 (95% CI 0.978; 1.13). Higher DAS assoc with diabetes. @RheumNow #EULAR2022 OP0272 https://t.co/QVjphcD7MG https://t.co/Buj8VAIJ5x
Links:
Richard Conway RichardPAConway ( View Tweet)
Increased risk of aortic regurgitation and atrial fibrillation in radiographic axSpA pts when compared to general population. No significant risk for AV block (II-III). Unclear if treatment affects cardiac risk in these patients.
@RheumNow #EULAR2022 ABST#POST0146
Robert B Chao, MD doctorRBC ( View Tweet)
Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR2022 OP0277 https://t.co/oLmsrniKw6 https://t.co/2zDkuUzq0S
Links:
Richard Conway RichardPAConway ( View Tweet)
Schett et al. CAR-T in SLE, case series 4 patients. Effective in inducing clinical remission in all 4 refractory patients. Looks like #rheummadness may have been (almost) correct @DavidLeverenz ! @RheumNow #EULAR2022 OP0279 https://t.co/frAU8COFs8
Links:
Richard Conway RichardPAConway ( View Tweet)
Do different therapies affect GCA PET scores differently?
n=47 LV-GCA pts, Padua, serial PET
(similar to prev @KQuinnRheum @petercgrayson work)
Need more protocolised data
but can't help but feel steroids alone doesn't quite touch the sides for GCA
POS0813 #EULAR2022 @RheumNow https://t.co/Y1sGmpNyDc
David Liew drdavidliew ( View Tweet)
In case there was doubt:
- steroid toxicity is real in GCA
- giving steroid-sparing therapies (TCZ, MTX) early makes a difference
just something to not forget when your next new GCA patient rolls in the door?
POS0805 #EULAR2022 @RheumNow https://t.co/2wGV3M8wZD
David Liew drdavidliew ( View Tweet)
COVID-19 mostly mild for majority of SpA patients.
Steroid use associated with more severe COVID-19 outcomes (OR 3.15).
TNFi found to be protective! (OR 0.26)
@RheumNow #EULAR2022 ABST#OP0254
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 Debate happening now:
📺⚕️Telemedicine: Salvation or necessary evil?
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Older age, HTN, dyslipidemia, CKD, cancer hx, and chronic liver disease co-morbidities increased risk of COVID19 severity. PMR was the only R-IMID identified and RTX tx also increased risk of severe COVID19. #EULAR2022 POS0203 @RheumNow https://t.co/TnhRnlWkX2
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2022 POS0196 found 9% of post-COVID19 patients developed MSK symptoms. @RheumNow https://t.co/YFT83TjXFL
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Yeoh @SuAnnYeoh1 @rheum_covid Factors assoc severe COVID outcomes in IIM. Age, male, high disease activity, 2+ comorbidities, pred>7.5mg, RTX, assoc hospitalisation or death @RheumNow #EULAR2022 OP0252 https://t.co/PvCeSX8UvF https://t.co/RaISpeUNsH
Links:
Richard Conway RichardPAConway ( View Tweet)